MP59: Bladder Cancer: Non-Invasive III

Poster Session Moderator(s)

• BG

  Boris Gershman, MD

  Beth Israel Deaconess Medical Center
• 

  Sumeet Bhanvadia, MD

  University of Southern California
• 

  Arturo Mendoza-Valdés, MD

  Hospital Medica Sur

Presentations:

• 1:00 PM – 2:15 PM

  MP59-01: Urine microRNAs as liquid biopsy assay for predicting response to intravesical BCG therapy
  

  Poster Presenter: Anirban Mitra, MD, PHD
• 1:00 PM – 2:15 PM

  MP59-02: Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study
  

  Poster Presenter: Nari Kim, PhD – Cedars-Sinai
• 1:00 PM – 2:15 PM

  MP59-03: A urine-based mutation-methylation assay for the surveillance of high risk non-muscle invasive bladder cancer patients
  

  Poster Presenter: Joep Jacobus De Jong – Erasmus MC
• 1:00 PM – 2:15 PM

  MP59-04: Bladder cancer recurrence monitoring by urinary extracellular vesicle RNA biomarkers
• 1:00 PM – 2:15 PM

  MP59-05: Frequency of Fibroblast Growth Factor Receptor Alterations and Association With Bacillus Calmette-Guerin Outcomes in a Real-World Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) Study
  

  Poster Presenter: Florus Christiaan De Jong – Erasmus MC
• 1:00 PM – 2:15 PM

  MP59-06: PD-L1 Expression and BCG Response in Non-Muscle Invasive Bladder Cancer
  

  Poster Presenter: Thomas S. Gerald, MD
• 1:00 PM – 2:15 PM

  MP59-07: Does the Urinary Microbiome Profile Change after Treatment of Bladder Cancer?
  

  Poster Presenter: Yousuf Omar Ramahi, BS
• 1:00 PM – 2:15 PM

  MP59-08: Disparities in the Prevalence and Management of High-Risk Non-Muscle Invasive Bladder Cancer
  

  Poster Presenter: Angela Estevez, MD – Beth Israel Deaconess Medical Center
• 1:00 PM – 2:15 PM

  MP59-09: Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in african american patients
  

  Poster Presenter: Stephen J. Freedland, MD (he/him/his)
• 1:00 PM – 2:15 PM

  MP59-10: Evaluating Ex Vivo Innate Immune Training as a Predictive Measure of Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer
  

  Poster Presenter: Song Jiang, MD, PHD
• 1:00 PM – 2:15 PM

  MP59-11: En bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-analyses of its differential effect on its safety, histopathology and, recurrence
  

  Poster Presenter: Takafumi Yanagisawa, MD,PhD
• 1:00 PM – 2:15 PM

  MP59-12: DEpth of Endoscopic Perforation (DEEP scale): a new classification to predict early post-operative outcomes in the endoscopic treatment of bladder cancer.
  

  Poster Presenter: Pietro Diana, MD
• 1:00 PM – 2:15 PM

  MP59-13: Bladder tumor accurate radiofrequency resection: 38 cases reports.
  

  Poster Presenter: Shengkun Sun, MD, PHD
• 1:00 PM – 2:15 PM

  MP59-14: Cross-Sectional Study Assessing Utilization Patterns of Combination Intravesical Gemcitabine and Docetaxel in the Management of Bladder Cancer
  

  Poster Presenter: Andrew Gabrielson, MD (he/him/his)
• 1:00 PM – 2:15 PM

  MP59-15: Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the treatment of BCG Naïve Non-muscle invasive Urothelial Carcinoma of the Bladder: Updates from a Phase 2 Trial
  

  Poster Presenter: Sunil H. Patel, MD
• 1:00 PM – 2:15 PM

  MP59-16: Sequential Intravesical Valrubicin and Docetaxel for the treatment of Non-Muscle Invasive Bladder Cancer
  

  Poster Presenter: Ian Mitchell Mcelree, BS, MS
• 1:00 PM – 2:15 PM

  MP59-17: Development and internal validation of a predictive model for recurrence-free survival in pTa low-grade bladder cancer
  

  Poster Presenter: Jorge A. Daza, M.D
• 1:00 PM – 2:15 PM

  MP59-18: Incidence and Outcomes of Nodal Metastasis in Clinically Non-Muscle Invasive Bladder Cancer
  

  Poster Presenter: Muhannad Alsyouf, MD
• 1:00 PM – 2:15 PM

  MP59-19: Update of TRUCE-02: An Open Label, Single-arm, Phase 2 Study of Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma (HR-NMIBC) Which is Not Completely Resectable.
  

  Poster Presenter: Yuanjie Niu
• 1:00 PM – 2:15 PM

  MP59-20: [18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with high-risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
  

  Poster Presenter: Massimo Lazzeri, MD